Welcome to LookChem.com Sign In|Join Free
  • or
(E/Z)-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid Methyl ester is a complex organic compound with a unique molecular structure that features a 3α-hydroxy group, a 6-ethylidene group, a 7-keto group, and a 5β-cholan core. It is a methyl ester derivative, which means it has a methyl group attached to the carboxylic acid moiety. (E/Z)-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid Methyl ester is characterized by its potential to exist in both E and Z geometric isomers, which can influence its properties and applications.

863239-59-2

Post Buying Request

863239-59-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

863239-59-2 Usage

Uses

Used in Pharmaceutical Industry:
(E/Z)-3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oic acid Methyl ester is used as a reactant in the preparation of dual agonists of nuclear and membrane bile acid receptors. This application is significant because bile acid receptors play crucial roles in various physiological processes, including the regulation of cholesterol and glucose homeostasis, as well as the modulation of inflammation and energy metabolism. By acting as dual agonists, these compounds can potentially offer therapeutic benefits in treating a range of conditions, such as metabolic disorders, liver diseases, and inflammatory conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 863239-59-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,3,2,3 and 9 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 863239-59:
(8*8)+(7*6)+(6*3)+(5*2)+(4*3)+(3*9)+(2*5)+(1*9)=192
192 % 10 = 2
So 863239-59-2 is a valid CAS Registry Number.

863239-59-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (EZ)-3-hydroxy-6-ethylidene-7-keto-5-cholan-24-oic acid methyl ester

1.2 Other means of identification

Product number -
Other names methyl 3α-hydroxy-6-ethylidene-7-keto-5β-cholanate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:863239-59-2 SDS

863239-59-2Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 3α,7α-DIHYDROXY6α-ETHYL-5β-CHOLAN-24-OIC ACID

-

Page/Page column 26, (2019/08/12)

The present invention relates to an improved process for the preparation of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid compound of formula-1, represented by the following structural formula: Formula-1 The present invention also relates to process for the preparation of ethylene diamine and tertiary butyl amine salts of 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid which are useful in the preparation of pure 3α,7α-dihydroxy-6α-ethyl-5β-cholan-24-oic acid.

Compound for treating metabolic diseases as well as preparation method and application thereof

-

Paragraph 0170; 0180-0182, (2019/07/04)

The invention provides a compound for treating metabolic diseases, the compound has a structure represented by formula (I) or formula (II), or a racemate, a stereoisomer, a geometric isomer, a tautomer, a solvate, a hydrate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The compounds provided by the invention are FXR and/or TGR5 receptor activators, and the compounds havethe activity of activating FXR and/or TGR5 receptors, and can be used for preparing medicines for treating chronic liver diseases, metabolic diseases or portal hypertension.

Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist

Feng, Wei-Dong,Zhuo, Song-Ming,Zhang, Fu-Li

, p. 1979 - 1989 (2019/10/11)

The process to obtain ICH-grade quality obeticholic acid (OCA) was improved, and the overall yield was 25.9%. The critical process parameters were established to reduce or avoid process-related impurities. The formation mechanisms, purge pathways, and control strategies for these impurities were also discussed for the first time. An high-performance liquid chromatography instrument utilizing the charged aerosol detection technique was applied for an impurity content assay in OCA for the first time. The developed process was robust and suitable for manufacturing scale-up.

Synthesis method of obeticholic acid and intermediate

-

Paragraph 0022, (2018/05/16)

The invention discloses a synthesis method of obeticholic acid and an intermediate. The method specifically comprises seven steps: an oxidation reaction, an esterification reaction, a protection reaction, an Aldol reaction, hydrogenation reduction, hydrolysis and a carbonyl reduction reaction with raw materials including chenodeoxycholic acid, NBS, concentrated sulfuric acid, methanol, sodium iodide, trimethyl silicon chloride, trimethylamine, acetaldehyde, boron trifluoride diethyl etherate, palladium on carbon, hydrogen, NaOH and NaBH4. The synthesis method of obeticholic acid and the intermediate is high in yield, low in cost, environmentally friendly, easy to operate and suitable for industrialization.

New obeticholic acid preparation method

-

Paragraph 0032-0034, (2019/09/02)

The invention relates to an obeticholic acid (represented by a structure formula 7) preparation method, which has characteristics of less purification steps, simple and convenient operation, high yield and low environmental pollution, and is suitable for industrial production. The formula 7 is defined in the specification.

STEROID DERIVATIVE FXR AGONIST

-

Paragraph 0098; 0106, (2018/12/13)

The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.

3,7-di(t-butyldimethylsiloxy)-6-ene-5beta-cholan-24-oic acid methyl ester

-

Paragraph 0117; 0119; 0120; 0121, (2017/08/27)

The invention belongs to the technical field of medicines, relates to a method of preparing obeticholic acid through adopting 3,7-di(t-butyldimethylsiloxy)-6-ene-5beta-cholan-24-oic acid methyl ester as an intermediate, and particularly relates to the 3,7-di(t-butyldimethylsiloxy)-6-ene-5beta-cholan-24-oic acid methyl ester that is a chemical compound, a method of preparing the compound, and a use of the compound for preparation of the obeticholic acid. The invention also relates to a method of preparing the obeticholic acid. The method of preparing the obeticholic acid includes (1) preparing the 3,7-di(t-butyldimethylsiloxy)-6-ene-5beta-cholan-24-oic acid methyl ester and (2) preparing the obeticholic acid through adopting the 3,7-di(t-butyldimethylsiloxy)-6-ene-5beta-cholan-24-oic acid methyl ester as the intermediate.

METHODS OF PROMOTING HEPATIC REGENERATION

-

Page/Page column 22-23, (2017/04/11)

The present invention relates to methods of accelerating, promoting or increasing hepatic regeneration, or increasing liver mass in a subject, by using a compound of formula (A): or a pharmaceutically acceptable salt thereof, and wherein R1, R2, R3, R4, R5, R6, m, and n are as described herein.

Sulfonylurea derivative and pharmaceutical composition and application thereof

-

Paragraph 0138; 0139; 0149; 0150, (2017/04/25)

The invention relates to a preparation method and application of a sulfonylurea compound and a composition containing the same component as FXR and / or TGR5 agonist, the FXR and / or TGR5 agonist is a compound shown as a formula (I), or a pharmaceutically acceptable salt, a solvate, a prodrug, an isomer and a stable isotope derivative thereof. The compounds can be used for treatment of FXR and / or TGR5 mediated diseases including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity and other field.

A high-purity aobeiAobei cholic acid preparation method (by machine translation)

-

Paragraph 0072-0074, (2017/07/20)

The invention relates to a method for preparing high-purity aobeiAobei cholic acid. As shown in formula II compound chenodeoxycholic acid (CDCA) as the starting material, through oxidation, esterification, hydroxyl protection, ethylidene, catalytic hydrogenation, and carbonyl reduction of an ester of a reaction to obtain high-purity aobeiAobei cholic acid. The present invention provides a method of preparing aobeiAobei cholic acid with low toxicity, low pollution, high purity, stereoselectivity is good, there is little impurity content, mild reaction conditions, high safety, production simple operation and the like, and is suitable for industrial production. (by machine translation)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 863239-59-2